Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with unknown T790M mutation: a case report and review of literature

Abstract Background First- and second-generation anti-epithelial growth factor receptor tyrosine kinase inhibitors have shown great efficacy in the treatment of advanced adenocarcinoma with epithelial growth factor receptor mutations, but this efficacy is limited by certain resistance mechanisms, in...

Full description

Bibliographic Details

Published in:	Journal of Medical Case Reports
Main Authors:	Mariem Hachlaf, Sihame Lkhoyaali, Wydad Nadir, Hajar Lemsyeh, Brahim El Ghissassi, Hind Mrabti, Saber Boutayeb, Hassan Errihani
Format:	Article
Language:	English
Published:	BMC 2024-08-01
Subjects:	NSCLC EGFR mutation Gefitinib T790M mutation Osimertinib Cerebral oligo-progression
Online Access:	https://doi.org/10.1186/s13256-024-04706-w